| Project/Area Number |
22501054
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KODAMA Syouta 福岡大学, 医学部, 准教授 (90549338)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 癌 / 遺伝子治療 / 抗体療法 / 分子標的 / 遺伝子 |
|---|
| Research Abstract |
We have recently developed the fiber modified adenovirus vector (Adv-FZ33). This vector can binds immunoglobulin-G (IgG) with high affinity. We demonstrated that monoclonal antibody (mAb) screened by Adv-FZ33, which is capable of binding to suitable target antigens on pancreatic cancer cell lines. Through this screening, we established twenty different mAbs. Among these mAbs, F2-27 is highly selective for cancer cell. The target antigens were identified as ** by MALDI-TOF mass spectrometry. These antigens were expressed in several cancer cell lines, including gastric, lung, and prostate cancer. We generated Ax3CMTK-FZ33 (tk-FZ33), which is an Adv-FZ33 derivative vector expressing a therapeutic gene, HSV-tk. tk-FZ33 with F2-27 enhanced the cytotoxicity of GCV (ganciclovir) compared with control mAb. These data suggest that F2-27-targeted FZ33-mutant adenovirus-mediated gene delivery offers a strong and selective therapeutic modality against cancers.
|
